Less than six months after Nasdaq debut, Malaysia’s Alps Group pivots to bridge biotech access gap

[KUALA LUMPUR] Less than six months after its debut on the Nasdaq, Malaysia’s Alps Group is shifting its focus from research to execution, expanding into insurance and education as it seeks to close critical gaps in access to advanced medical technologies.

Alps’ push to build a full-stack ecosystem comes as it navigates the realities of being a newly listed biotech firm.

According to US Securities and Exchange Commission filings and Nasdaq data, Alps Group is in the early stages of commercialisation, reporting 12-month trailing revenue of around US$3.7 million and has yet to achieve profitability.